GlaxoSmithKline has faced its fair share of scrutiny over a study of its antidepressant Paxil in teenagers, with some experts claiming that the company wrote off harmful side effects linked to the med. Now, a re-analysis of the original study shows that the trial trumpeted Paxil's benefits while downplaying serious side effects including suicide.
And the winner is … everyone. GlaxoSmithKline chose both of its incumbent agencies to continue handling media planning and buying for its newly consolidated GSK Consumer Healthcare business.
Georgetown's Dr. R. Scott Turner tested a therapeutic grade formulation of resveratrol in Alzheimer's patients, looking at two suspected biomarkers for the disease, the soluble proteins amyloid beta 42 and Abeta 40. Abeta 40 levels remained level among the group getting purified resveratrol, while the control group registered telltale declines as their dementia worsened.
Immuno-oncology player Adaptimmune has dipped into the ranks of its Big Pharma partner GlaxoSmithKline to find a leader for its biometrics team. The move sees Trupti Trivedi join Adaptimmune as VP, head of biometrics.
GlaxoSmithKline has hitched its automation plans to Siemens. The deal makes Siemens the preferred automation supplier for production and R&D sites at GSK, positioning the conglomerate to shape how its partner incorporates advances in data integration into its operations.
The Centers for Disease Control immunization committee stopped short of advising routine vaccination against meningitis B, instead leaving the decision up to doctors and families. And now, U.S. universities are tackling MenB vaccination in a multitude of ways.
The CDC's Advisory Committee on Immunization Practices has stopped short of recommending routine meningitis B immunization, leaving the decision to doctors and families whether young adults aged 16 to 23 should be vaccinated. Result? U.S. universities are taking varying approaches when it comes to MenB jabs and their students.
Immunotherapy developer Agenus, looking to further invest in its immuno-oncology pipeline, plans to temporarily cash out of a deal with GlaxoSmithKline to grab $115 million in exchange for royalties it once held on an adjuvant for GSK's malaria and shingles vaccines.
GlaxoSmithKline's respiratory business, struggling in the face of Advair price cuts, could use the few billion dollars analysts predicted it could generate if newcomer Breo aced an outcomes study. But no dice, the company reported Tuesday.
GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk patients with COPD, says that study failed.